Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan

Clinical Therapeutics

Volumn 29, Issue 10, 2007, Pages 2256-2267

  Shiroiwa, Takeru ^a   Fukuda, Takashi ^a   Tsutani, Kiichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

antibodies monoclonal; colorectal neoplasms; cost benefit analysis; drug therapy; neoplasm metastasis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; METASTASIS; MULTIPLE CYCLE TREATMENT; REGRESSION ANALYSIS; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; HEALTH CARE COSTS; HUMANS; JAPAN; NEOPLASM METASTASIS; REGRESSION ANALYSIS;

EID: 36248953225     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.10.013     Document Type: Article

References (36)

1. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition and prevention of cancer: A global perspective (1997), American Institute for Cancer Research, Washington, DC
2. Dynamic statistics of population [in Japanese]. 2005 ed (2007), Ministry of Health and Labor, Tokyo, Japan
3. Meyerhardt J., and Mayer R. Systemic therapy for colorectal cancer. N Engl J Med 352 (2005) 476-487
4. Kelly H., and Goldberg R. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 23 (2005) 4553-4560
5. Buyse M., Thirion P., Carlson R., et al., for the Meta-Analysis Group in Cancer. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Lancet 356 (2000) 373-378
6. Saltz L., Cox J., Blanke C., et al., for the Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000) 905-914
7. Douillard J., Cunningham D., Roth A., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. [published correction appears in Lancet. 2000;355:1372]. Lancet 355 (2000) 1041-1047
8. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
9. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
10. Kim K., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
11. National Comprehensive Cancer Network Colon Cancer Panel Members. Clinical practice guidelines in oncology-v.2.2006 colon cancer (2006)
12. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
13. Kabbinavar F., Hurwitz H., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
14. Kabbinavar F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in firstline metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
15. Hurwitz H., Fehrenbacher L., Hainsworth J., et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for firstline metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
16. Hochster H., Hart L., Ramanathan R., et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 25 Suppl (2006) 3510 Abstract
17. Giantonio B., Catalano P., Meropol N., et al., for the Eastern Cooperative Oncology Group. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007) 1539-1544
18. National Center for Biotechnology Information. PubMed: A Service of the National Library of Medicine and the National Institutes of Health [NIH Web site]
19. http://www.ncbi.nlm.nih.gov/sites/entrez/ Accessed June 2007
20. UpToDate: Putting General Information into Clinical Practice [UpToDate Web site]
21. http://www.uptodate.com/ Accessed June 2007
22. American Society of Clinical Oncology [Web site]
23. http://www.asco.org/portal/site/ASCO Accessed June 2007
24. Siegel J., Weinstein M., Russell L., and Gold M. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276 (1996) 1253-1258
25. National health insurance drug price standard [in Japanese] (April 2006), JIHO, Tokyo, Japan
26. Reimbursement schedule of social insurance and insurance for the elderly [in Japanese] (April 2006), Social Insurance Research Laboratory, Tokyo, Japan
27. Tappenden P., Jones R., Paisley S., and Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 11 (2007) 1-146
28. Jones M., Hummel S., and Bansback N. A review of the evidence for the clinical and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer (2002), National Institute for Clinical Excellence http://guidance.nice.org.uk/page.aspx?o=28739
29. Tappenden P., Chilcott J., Ward S., et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 42 (2006) 2867-2875
30. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
31. Kris M., Hesketh P., Somerfield M., et al., for the American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. [published correction appears in J Clin Oncol. 2006;24:5341-5342]. J Clin Oncol 24 (2006) 2932-2947
32. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (2004), National Institute for Clinical Excellence [NICE Web site]. http://www.nice.org.uk/page.asp?o=201974. Accessed April 9, 2007
33. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 118 bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (2007) [NICE Web site]. http://guidance.nice.org.uk/TA11/. Accessed April 9, 2007
34. Hillner B., Schrag D., Sargent D., et al. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 104 (2005) 1871-1884
35. Starling N., Tilden D., White J., and Cunningham D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/ best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 96 (2000) 206-212
36. McGregor M., and Caro J. QALYs: Are they helpful to decision makers? Pharmaco-Economics 24 (2006) 947-952